Original Research
Published on 08 May 2024
Examination of the role of mutualism in immune evasion
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2024.1406744
- 451 views
Type at least 3 characters
1,269 articles
Articles
Systematic Review
Published on 02 May 2024
The risk of endocrine immune-related adverse events induced by PD-1 inhibitors in cancer patients: a systematic review and meta-analysis
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2024.1381250
- 993 views
Original Research
Published on 02 May 2024
Predictive value of PD-L1 and TMB for short-term efficacy prognosis in non-small cell lung cancer and construction of prediction models
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2024.1342262
- 736 views
Original Research
Published on 02 May 2024
Increased co-expression of 4-1BB with PD-1 on CD8+ tumor-infiltrating lymphocytes is associated with improved prognosis and immunotherapy response in cervical cancer
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2024.1381381
- 693 views
Original Research
Published on 01 May 2024
High immune cell infiltration predicts improved survival in cholangiocarcinoma
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2024.1333926
- 705 views
Original Research
Published on 29 Apr 2024
Chordoma cancer stem cell subpopulation characterization may guide targeted immunotherapy approaches to reduce disease recurrence
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2024.1376622
- 912 views
Editorial
Published on 15 Apr 2024
Editorial: Emerging learnings in cell therapy: novel binding domains, universal CAR-T cells, and more
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2024.1404376
- 497 views
Review
Published on 10 Apr 2024
The role of alpha-fetoprotein in the tumor microenvironment of hepatocellular carcinoma
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2024.1363695
- 967 views
- 1 citation
Case Report
Published on 05 Apr 2024
Retreatment with immunotherapy in a patient with hepatocellular carcinoma who received immune checkpoint inhibitors after primary curative treatment: a case report
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2024.1321195
- 614 views
Original Research
Published on 03 Apr 2024
VISTA/CTLA4/PD1 coexpression on tumor cells confers a favorable immune microenvironment and better prognosis in high-grade serous ovarian carcinoma
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2024.1352053
- 855 views
Systematic Review
Published on 03 Apr 2024
Comparative efficacy and safety of targeted therapy and immunotherapy for HER2-positive breast cancer: a systematic review and network meta-analyses
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2024.1331055
- 929 views
Case Report
Published on 28 Mar 2024
Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2024.1328844
- 979 views
Study Protocol
Published on 28 Mar 2024
FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2024.1367450
- 1,352 views
Case Report
Published on 27 Mar 2024
Resection of unresectable hepatocellular carcinoma after conversion therapy with apatinib and camrelizumab: a case report and literature review
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2024.1280805
- 932 views
Review
Published on 26 Mar 2024
Research progress of immunotherapy against anaplastic thyroid cancer
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2024.1365055
- 1,166 views
Review
Published on 20 Mar 2024
Prospects and challenges of CAR-T cell therapy combined with ICIs
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2024.1368732
- 1,266 views